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~"~- -~ Symp~omatis Benefit o f  Calcium Antagonists in CAB 
Is Due to Improvement in Coronary Vssomotion 
Philipp A. Kaufnlann, J0rgen Fdelingsdorf, Otto M. Hess. Cordiology, 
University Hospital, Zurich, 8witzeriand 
Coronary vasomotion plays an impadant role in the regulation of myocar- 
dial peduslon. The effect of calcium antagonists on clinical symptomatology 
(functional ciassitisat!a', according to NYHA) and minimal luminal area (MLA; 
ram2) of *~e ~-~ ~ion was evaluated at rest and dudr~ bicycle exercise 
in 73 paLi~:nts wiL~ co,~nary artery disease. 42 patients served as controls 
{group 1) m~d :~ :eceived intrecoronary nicardipine or diltiazem (group 2). 
ML~, was detol~:~insd bybiplane quantitative comnan/angiography. Patient 
characteristics (~ge, ~:,:~ mass index, lipids, number of vessels diseased, 
mean workload) we:e s;:~:#~r fnbeth groups. 
l com~.-: c,~=,,,~m. ~,
An inverse relationship between NYHA and coronary vasomotion was 
found (r = 0.48, p < 0.005) which is abetished after administration ofcalcium 
antagonists. At the same time exertional angina is improved by the calcium 
blocker (32/42 vs. 8/31 group 1 vs. 2, p < 0.01). 
Conclusions: Calcium blockers improve clinical symptomatology by pre- 
venting exerctse-!nduced Coronary vasoconstriction. Thus, the beneficial ef- 
fect of calcium blockers is not only due to the vasodilatory effect on the 
periphery (loading conditions) 10ut appears to be due to the improvement in 
myocardial perfusion by elimination of stenosis vasoconstriction. 
3:15 
~'~- ]  Acute Vitamin C Administrat ion Improves 
Endothelium-Dependent Vesodiistlon in 
Insulin-Dependent Diabetic Patients 
Ferds K. Timimi, Henry H. "ring, Kimberly S. Boles, Mary-Anne Roddy, 
Peter Ganz, Mark A. Creager. Brigham and Women's Hospital, Boston, 
Massachusetts 
Insulin-dependent diabetes mallitus is associated with impaired endothelium- 
dependent vasodilation. Oxygen-darived free radicals may contribute to en- 
dothelial dysfunction by enhancing the degradation of endsthelium-dedved 
nitric oxide. We studied the effect of administration of v~rnin C (VIT C), 
an antioxident, on endothelium-dependent and -independent vasodilalion 
in eight subjects (age = 34:1:7 years) with IDDM and eight age/gender 
matched normal controls (NL). None of the subjects had ¢ardinvescolar dis- 
ease, hypertension, hyperchole~terolemia, or used tobacco. Forearm blood 
flow (FBF) was determined by venous occlusion plethysmography. Metha. 
choline chlonde (MET) and sodium nitroprusside (NIP) were infused via an 
intra-arteflal catheter at 0.3-10.0 mcg/min to assess endothelium-dependent 
and -Independent vssodilation, respectively, prior to and dudng concomitant 
intra-artedal Vff C infusion at 24 rag/rain, in IDDM, the FBF dose response 
curve to MET, but not NIP, was augmented by VR C infusion (p = 0.001). 
The peak FBF response to MET was increased from 15.7 ± 4.9 to 21.6 
5.4 ml/t00 mPmin by VlT C (p = 0.02). In NL, the FBF response to 
MET was not altered by VII" C (p = NS). In conclusion, the anttoxidant VIT 
C improves endothelium-dependent vasodilation in IDDM subjects. These 
findings suggest that o~:ygen-dedved free radicals contribute to impaired 
endothalium-depondent vasodilallon in IDDM, and may have a clinical role 
in modifying the course of vascular disease in these patients. 
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~'~- ]  IS Elevated Blood Pressure Hazard in the a Very 
Old? Insights From the Framingham Study 
William B. Kannol, Ralph B, D'Agostino, Janet Cobb, Halit Silbershalz, 
Boston University School of Medicine, Boston, MA 
Them is the pameption that in the very old (> 75 yrs.) hypertension may 
actually pmtact against mortality resulting in reluctance to treat hypertension 
aggressively in persons of advanced age. The relationship of blood pressure 
level to overall and cardiovascular mortality is examined in Framingham 
Study padicipants over age 75 yrs. free of cardiovascular disease (CVD) 
and also in those with interim CVD. Over the extended padod of follow-up 
them were 65 CV deaths in men and 108 in women in the sample free of CV 
events. 
Average annual incidence per 100: women ages 7594 yrs 
CVD Status Syst BP: 
74--119 120-139 140-159 160-179 180-300 
Free of CVD 9 19 19 32 43 
With CVD 79 49 43 48 62 
In subjects free of CVD there was a continuous graded increase in mortality, 
whereas in those with CVD there was a U-shsped curve of mortality in both 
sexes with a substantial excess mortality below 120 mmHG systolic blood 
pressure. 
Excess mortality reported in the aged with low blood pressure appears 
to be limited to those with CVD and may not be due to low blood pressure 
alone. 
2:15 
~ - ]  What Is a Significant Change in Left Ventricuisr 
Mass? An Assessment of  Measurement Variability 
of  Serial LV Mass Determination by 3D 
Echocardiogmphy 
Olakunle O. Aldnboboye, Zhanqing Shen, Pasha S. Gopal, Matthew 
J. Schnellbaecher, Donald L_ King. Columbia University and Mr. Sinai 
Medical Center, New York, NY 
Measurement of LV mass by 2D targeted M-mode echo using ABE criteria 
is a widely used method for assessing regression of LV mass during antihy- 
pertensive therapy. This method has a large test-retast inter-measurement 
vadability. Its reported 95% conho~nce interval for a single replicate mea- 
surement is 59 g (18A% of mean) [Goftdiener JS eta], JACC 1995; 25: 
424-30]. 3D echo has f~en extensively validated as an accurate method 
of LV mass measurement in vitro and in vivo. However, determination of 
its inter-measurement vadability for serial measurements of LV mass has 
not been performed. This study determines the confidence intervals for a 
single replicate measurement for determination of LV mass by 3D echo. 
30 unselected patients underwent wo complete 3D echo examinations in 
sequence by the same experienced observer. Between examinal~ons the 
patient was re-positioned. 8-10 short axis images were obtained using a 
real-time chocardlograph, acoustic spatial ocater, personal computer and 
the line of intersection display for operator guidance. Bouodados were man- 
ually traced and myocardial volume and mass computed. 
Results: 
n LV mass range Mean Measurem't 95% Cl 
Exam 1, Exam 2 Ex. 1,Ex.2 .V~iablrdy 
3D 30 116-435,110--421 ~31 g, 231 g 4% 9.1 g :1:25.8 g
Interpretation: A change of LV mass of _> 25.8 g (11.2% of mean) may be 
considered significant, ie, due in part to true biological change and not to 
measurement variability alone. 
Concius/on: 3D echo confidence intewals are approximately one-half as 
large as those for 2D targeted M-mode echo indicating that 3D echo has a 
signitican~ lower inter-measurement variability than 2D targeted M-mode 
echo. 30 echo is supedor to 2D targeted M-mode echo for assessment of LV 
mass. 
2:30 
~Long Acting Calcium Channel Blockers Nifedipine 
GITS and Amiodipine in HypertsnMon ~ Rate of  
Myocardial Infarction 
Robert A. Klonar, George Vetroyee. Good Samaritan Hospital, University of 
Southern California, Los Angeles, CA 
In a case.Conttolled retmspec6ve analysis, Psaty et al re.oi ly repoded an 
increase in the incidence of myocardial infarction (MI) among hypertensive 
patients receiving ca~um channal blcckem (CCB's, 16 MI'St1000 pt-years) 
compared to diuretics or beta blockem (10 Ml's/1000 pt-yeere). However 2 
out of 3 of the CCB's used in the study were short acting CCB's. There is little 
published ata on MI rate with newer once-a-day, long acting, CCB's which 
lack large fluctuations in peak to trough chug concentrations. We examined 
Ptizer's clinical data base for the long-acting CCB amlodipine and nifedipine 
GITS (gastrointestinal therapeutic system) in hypertension studies. For all 
hypertension trials; 
T 
U 
E 
S 
D 
A 
Y 
~O 
R 
A ,  
I._ 
178A ABSTRACTS-Oral JACC February 1996 
grub, # of pls Total # of Pt months MI rate per 
with MI pts. Exposure T~me 1000 pt - yrs 
Ntfedfp~na GfTS 4 2.629 9,247 5.2 
Amlod~ne 22 25.853 68,675 3.9 
In a subset of comparative trials the incidence of MI among 1372 lots re- 
calving nifedipine GITS was 3.3/1000 pt-years while among 621 10ts receiving 
active agents other than CCB's it was 5.111000 pt-years (p = NS); and the 
incidence of MI among 3748 patients receiving amlodipine was 4.3/1000 
pt-ysars while among 927 patients receiving active agents other than CCB's 
it was 2.2/1000 pt-years (p = NS). These data st%'~ort the concept hat 
the lang.acting CCB's nifedipine GITS and amlodipine are safe for treating 
hypertension. 
2:45 
~7"~'-~--~ Heart Rate Calcium Antagonists (HRL-CA) Lowering 
in Hypertensive Post MI Pctlents 
Franz H. Messedi. William E. Baden, Jargen Fischer Hansan, Kenneth 
B. Schechtman. Ochsner Medical Institutions, New Orleans, LA; 
Washington University, $1. Louis, MO 
Two recent publications (JAMA 1995;274:620 and Circulation 1995;92:1328) 
have cast doubt on the safety of CAs. Previous mete-analysis (Am d Cardlol 
1991;67:1295) has shown that in the post MI patient not all CAs are cre- 
atsd equal and that some dihydropyddine CAs may be detrimental, whereas 
HRL-CAs (diltiazemNerapamil) may be beneficial. The present data are 
based on a post hoc analysis o1 pooled data obtained from 5,677 post MI 
patients, randomized to either a HRL-CA or placebo in the first and second 
Danish Verapamil Infarction Tdals (DAVIT I and II) and the Muificentsr Dil- 
tiazem Post Infarction Tdal (MDPIT). Mean follow-up was 550 4- 376 days, 
all-cause mortality was 16.3% in hypertensives (HTS) and 12.0% in nor- 
motensives (NTS), and event rates (death or MI) were 24.4% vs 17.8%. 
Mortality was slightly lower in patients on HRL-CAs than in those on placebo 
in both HTS (15.1% vs 17.5%) and NTS (11.7% vs 12.4%). However, cu- 
mulative event rates were significantly reduced by HRL-CAs in HTS as 
follows: 
Hypertensive Normotensive 
HRL-CA 142/667 21.4% 372/2159 17.2% 
Placebo 1801658 27.4% 402/2190 18.4% 
p = 0.004 0.319 
After adjusting for age, gander, a history of previous MI, and diabetes using 
Cox regression, the use of HRL-CAs in HTS was associated with significantly 
reduced event rates (p = 0.016), adjusted sk ratio 0.76 (95°/= confidence 
bounds ranging from 0.61-0.95). We conclude that treatment with HRL-CAs 
in HTS post MI patients significantly diminishes event rate whereas little 
effect is seen in NTS subjects. These data with HRL-CAs are in contrast 
with other r~.ports on dihydropyddine CAs showing no effect or an increase 
in events. 
3:00 
~ Effect of Gender on Relative Efficacy of Isradipine 
vs Hydrochlorothlazlde for Reduction of Left 
Ventdeuler Mass 
vasilios Papademetriou, John Gottdiener, Puneet Narayan. Veterans Affairs 
and Georgetewn University Medical Centers, Washington, D.C. 
In patients with hypertensive LVH, reduction of LV mass is a desirable goal of 
drug therapy. However, comparative data between men and women is scarce. 
In this 18 center single-blind, randomized trial we compared isradipine (ISR) 
and hydrochlorofhtazlde (HCTZ) In 134 pts (age 57 ± 10 years, BP 164 
21/110 ± 10 mm Hg, echo LVM 345 + 80 g ASE, 26 women). At 3 and 
6 months of therapy decreases in septal and posterior wall thickness were 
similar between ISR and HCTZ. However, decrease in LV mass was greater 
with HCTZ (-43 g) vs ISR (-11 gr, P < 0,01) due to decrease in diastolic LV 
size (-2.8 ram). Comparing the response of men and women the following 
results were obtained: 
LV Mass Change from Baseline 
Isredipine HGTZ 
Men (n=74) Women (n = 15) Men (n = 34) Women (n = 11) 
3Me -10.8' -17.3 -363** -7.6 
6 Me -7.3 -21.1 -48.1** -15.3 
2 Wk -8.2 0.8 -30.6 ,° -2.9 
Post 
*P < 0.03, **P = 0.001 ;P = Change from baseline 
It is concluded that LV mass reduction with HCTZ was limited to men. The 
response to ISR was small overall with a trend of greater LV mass reduction 
in women. Futlher studies are needed to confirm this observation, 
3:15 
~6- -~ Gender Differences in the Relationship Between 
Oisstollc Function and Oxygen Consumption in 
Hypertensive Subjects 
All G. Gheravi, Joseph A. DiamOnd, Neit L. Coplan, Adam Y. Goldman, 
Jeffrey S. Jhaog, Man~n Steinmelz, Robert A. Phillips. Mount Sinai School 
of Medicine & Lenox Hill Hospital, New York, NY 
Previous tudies have suggested that diastolic function is a major determinant 
of exercise capacity and oxygen consumption (VO2) in hypertension. To 
further evaluate the elfects of gender on determinants of VO2 (cc/kg/min), 
we studied 48 sedentary, asymptomatic, untreated hypertensive subjects (M 
= 31, F = 17; office BP = 1651107 + 19/12). All subjects underwent: 1) 24 hour 
ambulatory blood pressure monitoring, 2) resting 2-D directed M-mode and 
LV inflow Doppler echecardiography, 3) graded maximal bicycle ergometry 
with VO2 measurement. There wore no gender differences in age, BMI, 
office and 24 hr BP, resting heart rate, peak early (E), late (,6,) mitral inflow 
velocities and A/E ratio. Women had signflicantly lower LV mass, peak VO2 
and VO2 at anaerobic threshold. In men, peak VO2 was inversely related 
to peak A (r = -0.62, p < 0.0005), and age (r = -0.43, p < 0.02). On 
stepwise multiple regression analysis, only peak A remained signflicantly 
related to I~k  VO2 in men (r 2 = 0.39, P < 0.001). In women, there was no 
relationship ~oetwean any measure of diastolic function and VO2 at various 
levels o! exercise. On multiple regression analysis, only peak exercise BP 
was directly related to peak VO2 in women (r 2 = 0.33, P < 0.03). There 
are significant gender differenCes in determinants of VO2 in hypertensive 
subjects. Doppler determined iastolic function is a major predictor of VO2 
in men but not in women. 
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4:00 
F7-6"1---1"-1 Randomized Trial of  Coronary Stent and Balloon 
Angloplasty in the Treatment of  Saphenous Veln 
Graft Stenosis 
John S. Douglas, Jr., Michael P. Savage, Steven R. Bailey, Cad J. Pepine, 
Jeffrey A. Wemer, Paul A. Overlie, Jeffrey A. Bdnker, David Fischman, 
Sheldon Goldberg, Spencer B. King III, SAVED Trial Investigators. Emory 
University School of Medicine, Atlanta, GA 
To compare the outcome of Palmaz-Schatz coronary stent (S) with balloon 
angioplasty (B), 215 patients with clinical evidence of ischemla and focal 
de novo vein graft stecoses were randomized at 12 centers. Demographic 
and clinical features of S and B groups were similar. Clinical events at 30 
days are reported in all patients and angiographic follow-up in ~ of eligible 
patients (last patient will be eligible for follow-up anglo in December 1995). 
Procedural success without cardiac complication was achieved in 90% of S 
and 78% of B patients (P < 0.015). 
Slant BallOOn P 
Clinical Events (%) at 30 days (IV = 215) 
Oeath 4 3 NS 
Non-QMTIQ wave MI 2/2 8/1 O.O59/NS 
CABG 2 4 NS 
Femoral repair 3 2 NS 
Transluelon I f 1 0.003 
Quantitative Anglogralohy (IV = 152 with 6 Month Follow-up) 
Baseline MUD (ram) 0.90 0.95 NS 
Postprocedura MLD (ram) 2.81 2.16 <0.0001 
MLD at 6 months tmm I 1.72 1.50 NS 
Immediate gain (mm) 1.90 1.19 <0.0001 
Lafe loss (ram) 1.I0 0.66 0.005 
Net gain (ram) 0.79 0.51 0.069 
Thus, stenting was associated with a higher procedural sucCess rate, 
a larger improvement in MLD, and a trend toward fewer non-Q MI, but 
significantly more transfusions. Interim analysis of late angiographic follow- 
up demonstrates ignificantly greater late lumen loss but a trend toward 
greater net gain after stenting. Complete six-month angiographic and clinical 
outcomes will be reported. 
